GT Biopharma GTBP Stock
GT Biopharma Price Chart
GT Biopharma GTBP Financial and Trading Overview
| GT Biopharma stock price | 0.3 USD |
| Previous Close | 0.31 USD |
| Open | 0.31 USD |
| Bid | 0.28 USD x 100 |
| Ask | 0.29 USD x 100 |
| Day's Range | 0.31 - 0.31 USD |
| 52 Week Range | 0.26 - 1.37 USD |
| Volume | 74K USD |
| Avg. Volume | 1.01M USD |
| Market Cap | 14.03M USD |
| Beta (5Y Monthly) | 0.903 |
| PE Ratio (TTM) | 0.059692897 |
| EPS (TTM) | 5.21 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3 USD |
GTBP Valuation Measures
| Enterprise Value | 8.84M USD |
| Trailing P/E | 0.059692897 |
| Forward P/E | -0.028796295 |
| PEG Ratio (5 yr expected) | 1.05 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.8875 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
GT Biopharma Stock Price History
| Beta (5Y Monthly) | 0.903 |
| 52-Week Change | -73.15% |
| S&P500 52-Week Change | 18.35% |
| 52 Week High | 1.37 USD |
| 52 Week Low | 0.26 USD |
| 50-Day Moving Average | 0.37 USD |
| 200-Day Moving Average | 0.5 USD |
GTBP Share Statistics
| Avg. Volume (3 month) | 1.01M USD |
| Avg. Daily Volume (10-Days) | 460.41K USD |
| Shares Outstanding | 45.11M |
| Float | 42.52M |
| Short Ratio | 4.63 |
| % Held by Insiders | 5.70% |
| % Held by Institutions | 4.70% |
| Shares Short | 3.92M |
| Short % of Float | 10.87% |
| Short % of Shares Outstanding | 10.87% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -158.15% |
| Return on Equity (ttm) | -113.52% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -11380000 USD |
| Diluted EPS (ttm) | 5.21 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 4.96M USD |
| Total Cash Per Share (mrq) | 0.11 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.608 |
| Book Value Per Share (mrq) | 0.08 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -14426000 USD |
| Levered Free Cash Flow (ttm) | -8872375 USD |
Profile of GT Biopharma
| Country | United States |
| State | CA |
| City | San Francisco |
| Address | 315 Montgomery Street |
| ZIP | 94104 |
| Phone | 415 919 4040 |
| Website | https://www.gtbiopharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1 |
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Q&A For GT Biopharma Stock
What is a current GTBP stock price?
GT Biopharma GTBP stock price today per share is 0.3 USD.
How to purchase GT Biopharma stock?
You can buy GTBP shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for GT Biopharma?
The stock symbol or ticker of GT Biopharma is GTBP.
Which industry does the GT Biopharma company belong to?
The GT Biopharma industry is Biotechnology.
How many shares does GT Biopharma have in circulation?
The max supply of GT Biopharma shares is 45.11M.
What is GT Biopharma Price to Earnings Ratio (PE Ratio)?
GT Biopharma PE Ratio is 0.05765835 now.
What was GT Biopharma earnings per share over the trailing 12 months (TTM)?
GT Biopharma EPS is 5.21 USD over the trailing 12 months.
Which sector does the GT Biopharma company belong to?
The GT Biopharma sector is Healthcare.
GT Biopharma GTBP included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26416.8 USD — |
-0.47
|
6.34B USD — | 26359.27 USD — | 26700.68 USD — | — - | 6.34B USD — |
|
US Tech Health Care
IXHC
US
|
1340.4 USD — |
-2.01
|
— — | 1338.76 USD — | 1360.4 USD — | — - | — — |
- {{ link.label }} {{link}}
